A Phase I, Single-Institution Open Label, Dose-Escalation Trial With an Expansion Trial Cohort Evaluating the Safety and Tolerability of AZD6244 and IMC-A12 in Subjects With Advanced Solid Malignancies
Phase of Trial: Phase I
Latest Information Update: 30 Jan 2016
At a glance
- Drugs Cixutumumab (Primary) ; Selumetinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 30 Sep 2014 Status changed from active, no longer recruiting to completed, according to results published in the British Journal of Cancer.
- 14 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 10 Jan 2013 Additional lead trial centre added as reported by ClinicalTrials.gov.